Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access Remdesivir (RDV; GS-5734™)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04302766
Expanded Access Status : Available
First Posted : March 10, 2020
Last Update Posted : April 10, 2020
Sponsor:
Information provided by (Responsible Party):
U.S. Army Medical Research and Development Command

Tracking Information
First Submitted Date March 2, 2020
First Posted Date March 10, 2020
Last Update Posted Date April 10, 2020
 
Descriptive Information
Brief Title Expanded Access Remdesivir (RDV; GS-5734™)
Brief Summary Disease caused by 2019 Novel Coronavirus also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Detailed Description The treatment of communicable Novel Coronavirus (CODIV-19) of 2019 with Remdesivir (RDV; GS-5734™) also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Study Type Expanded Access
Expanded Access Type Intermediate-size Population, Treatment IND/Protocol
Intervention Drug: Remdesivir
Remdesivir (RDV,GS-5734) is a monophosphoramidate prodrug of an adenosine analog with potent activity against an array of RNA virus families including Filoviridae, Paramyxoviridae, Pneumoviridae, and Orthocoronavirinae, through the targeting of the viral RNA dependent RNA polymerase (RdRp).
Other Name: GS-5734
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Expanded Access Status Available
Contacts
Contact: Sandi K Parriott 301-619-6824 sandi.k.parriott.mil@mail.mil
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT04302766
Responsible Party U.S. Army Medical Research and Development Command
Study Sponsor U.S. Army Medical Research and Development Command
Collaborators Not Provided
Investigators Not Provided
PRS Account U.S. Army Medical Research and Development Command
Verification Date April 2020